{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-034544","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2025-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.605005+00:00","generated_at":"2026-05-18T09:06:38.463210+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Absci appoints Mary Szela to Board effective July 7, 2025; grants 178,400 share option","bullets":["Mary Szela appointed as Class III director; board expanded from six to seven members.","Receives initial option grant for 178,400 shares at closing price on grant date, vesting monthly over three years.","Will receive $40,000 annual cash retainer under Non-Employee Director Compensation Policy.","Szela currently serves as CEO, President and Director of Trisalus Life Sciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-034544","json":"https://secwatch.observer/filing/0001628280-25-034544.json","markdown":"https://secwatch.observer/filing/0001628280-25-034544.md","text":"https://secwatch.observer/filing/0001628280-25-034544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828025034544/0001628280-25-034544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828025034544/absc-20250707.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:06:38.463210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}